Protagenic therapeutics inc PTIX.US 總覽分析
PTIX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
PTIX 近期報酬表現
1172.89%
Protagenic therapeutics inc
1.99%
同產業平均
-0.64%
S&P500
與 PTIX 同產業的標的表現
- WAI Top kingwin ltd價值 -趨勢 4 分波段 2 分籌碼 -股利 1 分查看更多
PTIX 公司資訊
Protagenic Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The Company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead ingredient, a 41-amino-acid synthetic peptide, is used to treat a number of neuropsychiatric disorders, such as anxiety, depression, and post-traumatic stress disorder (PTSD). It operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels. In addition, it has a portfolio of earlier stage neuropeptides targeting the TCAP pathway that are in preclinical evaluation. The initial dosage form is intended as a subcutaneous injection but is also amenable to other routes of administration, including sublingually or intra-nasally.